Horm Metab Res 2011; 43(13): 980-983
DOI: 10.1055/s-0031-1291233
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Pioglitazone versus Simvastatin on Biomarkers of Inflammation in Patients on High Cardiovascular Risk

M. Hanefeld
1   Center for Clinical Studies – Metabolism and Endocrinology, Science and Technology Transfer, TU Dresden,  Dresden, Germany
,
F. Schaper
1   Center for Clinical Studies – Metabolism and Endocrinology, Science and Technology Transfer, TU Dresden,  Dresden, Germany
,
D. Appelt
1   Center for Clinical Studies – Metabolism and Endocrinology, Science and Technology Transfer, TU Dresden,  Dresden, Germany
,
W. Fuchs
2   Takeda Pharma GmbH, Aachen, Germany
› Author Affiliations
Further Information

Publication History

received 10 May 2011

accepted 19 September 2011

Publication Date:
08 November 2011 (online)

Abstract

High levels of fetuin-A has been linked to cardiovascular disease, possibly via modulating low-grade systemic inflammation. We performed a subanalysis from the PIOSTAT study to investigate a possible link between fetuin-A and the inflammatory biomarker hs-CRP. 66 nondiabetic individuals at cardiovascular risk were randomized to either pioglitazone, simvastatin, or the combination of both, and followed for 12 weeks. At study endpoint, correlations between serum fetuin-A, hs-CRP, blood lipids, PAI-1, MMP-9, HOMA-IR, and liver transaminases were investigated by Spearman rank correlation. Changes in fetuin-A concentration did not correlate to changes in hs-CRP (r=0.19, p=0.16). A positive correlation was found for change of HOMA-IR value (r=0.33, p=0.01) and for the AST/ALT ratio (p<0.05). Our data suggest that the previously observed correlation between elevated circulating fetuin-A and hs-CRP in epidemiological studies may not reflect a causal relationship in nondiabetic patients on high cardiovascular risk.